Case Report

Multidrug-Resistant Viridans Streptococcus (MDRVS) Osteomyelitis of the Mandible Successfully Treated with Moxifloxacin

Authors: Jocelyn Y. Ang, MD, Basim I. Asmar, MD

Abstract

Multidrug-resistant viridans group streptococcus (MDRVS) strains have emerged as important pathogens. Treatment of MDRVS infections is problematic. The use of fluoroquinolones for treatment of MDRVS osteomyelitis has not been established. We present the first case of MDRVS osteomyelitis of the mandible successfully treated with sequential intravenous then oral moxifloxacin, and review the literature on the subject.


Key Points


* Multidrug-resistant viridans group streptococci (MDRVS) have emerged as important pathogens.


* Therapeutic choices for treatment of MDRVS are limited.


* Moxifloxacin appears to be an effective and attractive option for the treatment of MDRVS infections, including osteomyelitis.


* Further studies are needed to confirm its safety and efficacy in children less than 18 years of age.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Doern GV, Ferraro MJ, Brueggemann AB, et al. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996;40:891–894.
 
2. Dan M, Keynan O, Feldbrin Z, et al. Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens. Diagn Microbiol Infect Dis 2004;48:283–286.
 
3. Malincarne L, Ghebregzabher M, Moretti MV, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 2006;57:950–954.
 
4. Metallidis S, Charokopos N, Nikolaidis J, et al. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. Int J Antimicrob Agents 2006;28:428–432.
 
5. Frippiat F, Meunier F, Derue G. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004;54:1158; author reply 1159.